Lantheus Holdings saw a key risk play out in 2025, as intensified competition for Pylarify led to lowered EPS guidance and a ...

On a YTD basis, Lantheus is outperforming its medical equipment peers by 3x; this wasn't the case until July, when the CMS came out with a new proposal. Even before the CMS' proposal, PYLARIFY was ...

Lantheus Holdings, Inc. (NASDAQ:LNTH) reported third quarter 2025 financial and operational results on November 6 th, producing sales of $384 million, a 1% increase compared to 3Q:24 levels. Pylarify ...

PYLARIFY ® (piflufolastat F 18) Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with ...

PYLARIFY has made a profound impact on the lives of patients battling prostate cancer. It is the number one ordered PSMA PET imaging agent in the U.S., and is a proven diagnostic backed by real-world ...

Lantheus Holdings (NASDAQ: LNTH) held its fourth-quarter and full-year 2024 earnings call on Feb. 26, 2025, highlighting achievements in its radiopharmaceutical portfolio and announcing strategic ...

Lantheus (LNTH) Holdings notes that the Centers for Medicare & Medicaid Services recently posted updated payment rates in Addendum B related to the final rule for the calendar year 2025 Medicare ...

The approval was based on data from the phase 2/3 OSPREY and phase 3 CONDOR trials that evaluated the diagnostic performance and safety of Pylarify injection. The Food and Drug Administration (FDA) ...

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. GE HealthCare this morning announced an exclusive ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved piflufolastat F 18 injection, a radioactive diagnostic agent designed to identify suspected ...

Prostate imaging drug Pylarify has become the first radiodiagnostic blockbuster, achieving over $1 billion in sales for 2024. The addressable market continues to expand. Start Your Mornings Smarter!